News | February 17, 2025
GSK’s Penmenvy approved by FDA to help protect against MenABCWY
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
Vaccine helps protect against five common disease-causing serogroups of Neisseria meningitidis (A, B, C, W and Y)
No safety signals related to the vaccine candidate were identified
The company has withdrawn all litigation against Vikas Lifecare Limited post withdrawal of the Alwar Case by VLL
Approval is based on positive data from the Phase 3 ECHELON-3 trial
The company anticipates 2025 worldwide sales to be between $64.1 billion and $65.6 billion
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Revenue from Operations for Q3 FY25 was Rs. 454.33 crore,
Biocon’s subsidiary Biocon Biologics Limited, which also participated independently in the assessment for the first time, reported an S&P Global ESG Score of 53
The camp, operational daily from 12 PM to 4 PM, offers free health check-ups, blood pressure monitoring
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
Subscribe To Our Newsletter & Stay Updated
